Amany Ameen SLEEM, Nermeen M. SHAFFIE, Omar Mohamed ABDEL-SALAM

Effect of Viscum album on acute hepatic damage caused by carbon tetrachloride in rats

To investigate the effect of Viscum album, a plant used for the treatment of hepatocellular carcinoma that has immune-modulating properties, on acute hepatic injury in rats. Materials and methods: Hepatotoxicity was induced by CCl4 orally (0.28 mL/kg). Rats received either Viscum album at 1 of 2 dose levels (0.1 or 0.2 mL/kg) once weekly subcutaneously alone or with silymarin (25 mg/kg, orally), or silymarin (25 mg/kg) once daily orally for 1 month, starting at the time of administration of CCl4. Liver damage was assessed by determining liver serum enzyme activities and by hepatic histopathology. Results: Viscum album administration decreased the increases in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), and also prevented the development of hepatic necrosis caused by CCl4. The effect of Viscum album was dose-dependent. Viscum album administered at 0.1 or 0.2 mL/kg caused significant reduction in the elevated plasma ALT by 51.2% and 65.6%, AST by 52.6% and 61.1%, and ALP by 27.7% and 57.6%, respectively. In comparison, the elevated serum ALT, AST, and ALP levels decreased to 48.9%, 51.8%, and 30.8% of the controls, respectively, with 25 mg/kg of silymarin. Viscum album (0.2 mL/kg) administered together with silymarin resulted in 73.1%, 67.6%, and 65.8% decreases in serum ALT, AST, and ALP levels, respectively. Histopathologic examination of the livers of rats treated with CCl4 and administered Viscum album at 0.2 mL/kg showed marked restoration of the normal architecture of the liver tissue with minimal fibrosis. Conclusion: Results of the present study indicate that the administration of Viscum album in a model of liver injury induced by CCl4 in rats results in less liver damage.

Anahtar Kelimeler:

Key words: Viscum album, hepatic injury, rat, CCl4

Effect of Viscum album on acute hepatic damage caused by carbon tetrachloride in rats

Keywords:

Key words: Viscum album, hepatic injury, rat, CCl4,

PDF

___

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 5: 465-89. 9. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998; 93: 139-43.
Muriel P, Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 1990; 10: 275-79.
Muriel P, Garciapina T, Perez-Alvarez V, Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 1992; 12: 439-42.
Wu CG, Chamuleau RA, Bosch KS, Frederiks WM. Protective effect of silymarin on rat liver injury induced by ischemia. Virchows Arch B Cell Pathol 1993; 64: 259-63.
Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken, EO, Schuppan D. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 2001; 35: 392-8.
Feher J, Deak G, Muzes G, Lang I., Niederland V, Nekam K et al. Liver protective action of silymarin therapy in chronic alcoholic liver diseases. Orv Hetil 1989; 130: 2723-7.
Pár A, Roth E, Rumi G, Kovács Z, Nemes J, Mózsik G. Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C. Orv Hetil 2000; 141: 1655-9.
Lucena MI, Andrade RJ, De la Cruz JP, Rodriguez Mendizabal M, Blanco E, Sanchez de la Cuesta F. Effects of silymarin MZ- 80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 2002; 40: 2-8.
Mayer KÉ, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepatitis 2005; 12: 559-67.
Tusenius KJ, Spoek JM, Kramers CW. Iscador Qu for chronic hepatitis C: an exploratory study. Complement Ther Med 2001; 9: 12-6.
Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001; 7: 57-66, 68-72.
Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR. Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. Integr Cancer Ther 2003; 2: 345-52.
Happle R. Alternative medicine: really an alternative to academic medicine? Hautarzt 2000; 51: 439-43.
Paget GE, Barnes IM. Evaluation of drug activities. In: Laurence DR, Bacharach AL, editors. Toxicity tests. Vol. 1. London & New York: Academic Press; 1964. p.1-135.
Crowley LV. The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin Chem 1967; 13: 482-7.
Belfield A, Goldberg DM. Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 1971; 12: 561-73.
Tusenius KJ, Spoek AM, van Hattum J. Exploratory study on the effects of treatment with two mistletoe preparations on chronic hepatitis C. Arzneimittelforschung 2005; 55: 749-53.
Hajtó T, Hostanska K, Berki T, Pálinkás L, Boldizsár F, Németh P. Oncopharmacological perspectives of a plant lectin (Viscum album agglutinin-I): overview of recent results from in vitro experiments and in vivo animal models, and their possible relevance for clinical applications. Evid Based Complement Alternat Med 2005; 2: 59-67.
Van Huyen JP, Delignat S, Bayry J, Kazatchkine MD, Bruneval P, Nicoletti A et al. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 2006; 243: 32-7.
Bussing A, Bischof M, Hatzmann W, Bartsch F, Soto-Vera D, Fronk EM et al. Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res 2005; 25: 4753-7.
Gray AM, Flatt PR. Insulin-secreting activity of the traditional antidiabetic plant Viscum album (mistletoe). J Endocrinol 1999; 160: 409-14.
Orhan DD, Aslan M, Sendogdu N, Ergun F, Yesilada E. Evaluation of the hypoglycemic effect and antioxidant activity of three Viscum album subspecies (European mistletoe) in streptozotocin-diabetic rats. J Ethnopharmacol 2005; 98: 95- 102. 31. Radenkovic
M, Ivetic V, Popovic M, Mimica-Dukic N, Veljkovic
S. Neurophysiological effects of mistletoe (Viscum album L.) on
isolated rat intestines. Phytother Res 2006; 20: 374-7.
Pratt DS, Kaplan MM. Laboratory tests. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff ’s diseases of the liver. 8th ed. Vol. 1. Philadelphia: Lippincott-Raven; 1999. p.205-244.
Farghali H, Kamenikova L, Hynie S, Kmonickova E. Silymarin effects on intracellular calcium and cytotoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol Res 2000; 41: 231-7.
De La Puerta R, Martinez E, Bravo L, Ahumada MC. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 1996; 48: 968-70.